Meet the dirt cheap ASX 200 stock that could rocket 75%

Bell Potter thinks investors should be snapping up this stock while it is down in the dumps.

| More on:
A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neuren Pharmaceuticals Ltd (ASX: NEU) shares were out of form on Tuesday after getting caught up in the market selloff.

The ASX 200 stock ended the day 6% lower at $11.40.

This leaves the pharmaceutical company's shares trading within sight of their 52-week low of $10.90.

One leading broker thinks that investors should be seizing this opportunity to buy a quality company at deep discount to its true value.

What is the broker saying about this ASX 200 stock?

According to a note out of Bell Potter, its analysts have been pleased with the performance of the company's Daybue product, which it receives royalties from. It said:

Daybue CY24 US sales of US$348m was within guidance and slightly above consensus. Acadia's CY25 guidance for US sales is US$380-405m (9-16% growth). Our US$385m forecast is comfortably within this range and remains unchanged following the update. The US-only guidance implies CY25 royalties to NEU of US$41-44m, so not a major difference to NEU at either end of this range.

Most pleasingly, even the low end of CY25 guidance reflects HSD growth yoy, providing confidence in Daybue's continued growth outlook in the US excluding any Canadian or EU contributions. Note management expects Daybue 1Q25 US sales to have a similar QoQ seasonality decline as seen in 1Q24 before rebounding later in the year.

In light of this, the broker has reaffirmed its buy rating with a trimmed price target of $20.00.

Based on where the ASX 200 stock is currently trading, this implies potential upside of 75% for investors over the next 12 months.

Second asset for free

Bell Potter highlights at the current share price, the market is ascribing no value to Neuren's second asset. It explains:

Regarding catalyst timing, it will be ~2 years until the next major clinical catalyst, being the first Ph3 readout for NNZ-2591, which offers clear re-rating potential but remains some time away.

NEU has unrivalled balance sheet strength to prosecute future NNZ-2591 development yet effectively zero value is currently attributed to this asset, likely due to the Ph3 readout timing. We maintain our BUY recommendation which continues to be driven by a positive outlook on NNZ-2591. Licensing income from Daybue alone supports the current share price.

All in all, this could be an ASX 200 stock to buy. Especially if you're looking for exposure to this side of the market (and big potential returns!).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

three excited doctors with hands in the air
Healthcare Shares

Why Macquarie forecasts a 22% upside for this ASX All Ords healthcare stock

Macquarie expects a big rebound ahead for this ASX healthcare stock. But why?

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Healthcare Shares

Guess which ASX All Ords stock is jumping 9% on $1.6b market opportunity

This small cap is having a big day. But why?

Read more »

A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
Healthcare Shares

75% upside: Broker tips two ASX healthcare shares

This broker sees big potential in these two Australian healthcare companies 

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

What does the Macquarie Hospital Claims Index mean for ASX 200 health insurance stocks?

Macquarie shares its view on Medibank Private and NIB Holdings.

Read more »

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

2 ASX healthcare stocks making huge moves on big news

These shares are getting investors excited today. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »